Business Context and Reporting Period
Company: SANUWAVE Health, Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: March 31, 2010
Business Overview: An emerging global medical technology company focused on noninvasive, biological response activating devices (PACE technology) for regenerative medicine. The company is developing products for wound healing, orthopedic/spine, plastic/cosmetic, and cardiac conditions. Following the divestiture of its veterinary division in June 2009, the company has no FDA-approved products currently in commercialization in the United States.
Key Financial Metrics
| Metric | Q1 2010 | Q1 2009 |
|---|---|---|
| Revenues | $143,102 | $262,082 |
| Gross Profit | $95,458 | $201,800 |
| Gross Margin | 67% | 77% |
| Operating Loss | $(2,860,461) | $(1,998,444) |
| Net Loss | $(2,994,755) | $(1,823,466) |
| Loss Per Share (Basic/Diluted) | $(0.24) | $(0.17) |
| Cash and Cash Equivalents | $1,065,691 | $533,061 |
| Total Assets | $4,950,454 | $5,867,085 |
| Total Liabilities | $13,346,821 | $11,751,399 |
| Stockholders' Equity (Deficit) | $(8,396,367) | $(5,884,314) |
| Accumulated Deficit | $(41,655,036) | $(38,660,281) |
Debt Profile:
- Promissory Notes (Current): $1,001,556 (Issued in March 2010 to stockholders, due June 2010).
- Notes Payable, Related Parties (Non-Current): $9,105,161 (Includes notes to HealthTronics, Inc. and Prides Capital Fund I/NightWatch Capital Partners II).
Material Changes vs. Prior Period
- Revenue Decline: Revenues decreased 45% to $143,102, primarily due to declining sales of the legacy Evotron device in Europe following the elimination of the European sales staff in 2009.
- Increased Operating Expenses:
- R&D Expenses: Increased 33% to $1,085,974, driven by higher costs for the ongoing dermaPACE clinical trial for diabetic foot ulcers as enrollment neared completion.
- G&A Expenses: Increased 28% to $1,598,524. This includes a significant increase in non-cash stock-based compensation ($483,270 vs. $133,696 in 2009). Excluding stock compensation, G&A expenses remained relatively flat.
- Depreciation: Increased 98% to $271,421, largely due to the reclassification of Ossatron device assets from "discontinued operations" to "continuing operations" in October 2009, restarting depreciation charges.
- Interest Expense: Increased 57% to $217,281 due to interest on related party notes issued in 2009.
- Discontinued Operations: No income from discontinued operations in Q1 2010, compared to $322,485 in Q1 2009 (related to the veterinary business sold in June 2009).
Outlook, Risks, and Management Commentary
Going Concern: The filing explicitly states that operating losses create substantial doubt about the company's ability to continue as a going concern. The company is economically dependent on future financing to fund operations.
Clinical Progress:
- Completed enrollment of 206 patients for the dermaPACE IDE wound care clinical study (diabetic foot ulcers) at 24 sites.
- Final study data is expected in Q4 2010.
- Regulatory submission plans with the FDA are being finalized.
Liquidity and Capital Resources:
- Cash balance of $1.1 million as of March 31, 2010.
- Net cash used by operating activities was $1.72 million.
- Financed operations in Q1 2010 via $1 million in promissory notes issued to stockholders.
- Management anticipates raising additional capital through public/private equity offerings, warrant exercises, or debt financing.
Risks:
- Uncertainty regarding the timing and cost of clinical trials and regulatory approvals.
- Potential dilution of shareholders if equity financing is pursued.
- Restrictive covenants if debt financing is secured.
- Legal proceedings regarding patents and a breach of contract lawsuit (defended by HealthTronics) seeking over $3 million.
Investor Verification Checklist
- Financing Needs: Verify the company's ability to secure additional capital given the "going concern" warning and $1.7M quarterly cash burn.
- Debt Maturity: Confirm the repayment status of the $1 million in promissory notes due in June 2010 and the $9.1 million in related party notes.
- Clinical Trial Results: Monitor the Q4 2010 release of data from the dermaPACE diabetic foot ulcer study, which is critical for future commercialization.
- Revenue Sustainability: Assess the viability of remaining European sales of legacy devices as the company transitions to a US-focused R&D model.
- Legal Exposure: Review the status of the pending breach of contract lawsuit and patent litigation mentioned in the 10-K.